Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
34.2 EUR | -1.16% | -0.29% | -14.97% |
Apr. 25 | Boiron SA Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Feb. 02 | Boiron: nearly 600,000 shares tendered to the OPAS | CF |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- With regards to fundamentals, the enterprise value to sales ratio is at 0.94 for the current period. Therefore, the company is undervalued.
- The opinion of analysts covering the stock has improved over the past four months.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- The company's currently anticipated earnings per share (EPS) growth for the next few years is a notable weakness.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- Over the past twelve months, analysts' opinions have been revised negatively.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-14.97% | 648M | B | ||
+43.17% | 6.29B | B- | ||
-14.69% | 4.55B | C+ | ||
+6.95% | 3.27B | C | ||
-8.17% | 3.23B | B- | ||
-1.76% | 2.56B | - | D+ | |
+50.20% | 2B | - | ||
-7.85% | 1.68B | - | - | |
-0.40% | 1.64B | - | - | |
+54.97% | 1.6B | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- BOI Stock
- Ratings BOIRON